Cyclacel Pharmaceuticals Announces Multiple Presentations At American Association of Cancer Research Annual Meeting
April 16, 2009 07:00 ET
|
Cyclacel
BERKELEY HEIGHTS, N.J., April 16, 2009 (GLOBE NEWSWIRE) -- Cyclacel Pharmaceuticals, Inc. (Nasdaq:CYCC) (Nasdaq:CYCCP) announced today the presentation of preclinical data from its two most advanced...
Cyclacel Pharmaceuticals Announces Suspension of Quarterly Dividend On 6% Convertible Exchangeable Preferred Stock
April 08, 2009 07:00 ET
|
Cyclacel
BERKELEY HEIGHTS, N.J., April 8, 2009 (GLOBE NEWSWIRE) -- Cyclacel Pharmaceuticals, Inc. (Nasdaq:CYCC) (Nasdaq:CYCCP) (the "Company") announced that its Board of Directors passed a resolution to...
Cyclacel Pharmaceuticals Announces Financial Results for Fourth Quarter and Year Ended December 31, 2008
March 31, 2009 16:01 ET
|
Cyclacel
BERKELEY HEIGHTS, N.J., March 31, 2009 (GLOBE NEWSWIRE) -- Cyclacel Pharmaceuticals, Inc. (Nasdaq:CYCC) (Nasdaq:CYCCP) announced today financial results and milestone highlights for the fourth quarter...
Cyclacel Pharmaceuticals to Announce Fourth Quarter 2008 Financial Results On March 31, 2009
March 24, 2009 07:00 ET
|
Cyclacel
BERKELEY HEIGHTS, N.J., March 24, 2009 (GLOBE NEWSWIRE) -- Cyclacel Pharmaceuticals, Inc. (Nasdaq:CYCC) (Nasdaq:CYCCP) will announce fourth quarter 2008 financial results on Tuesday, March 31, 2009....
Cyclacel Announces Phase 1 Data Published Elucidating Pharmacodynamics & Mechanism of Action of Seliciclib in Nasopharyngeal Cancer
March 05, 2009 07:00 ET
|
Cyclacel
BERKELEY HEIGHTS, N.J., March 5, 2009 (GLOBE NEWSWIRE) -- Cyclacel Pharmaceuticals, Inc. (Nasdaq:CYCC) (Nasdaq:CYCCP) announced publication of an investigator-sponsored Phase 1 study reporting...
Cyclacel Pharmaceuticals Advances Oral Sapacitabine Pivotal Trial Plan in Hematological Malignancies
February 06, 2009 07:00 ET
|
Cyclacel
BERKELEY HEIGHTS, N.J., Feb. 6, 2009 (GLOBE NEWSWIRE) -- Cyclacel Pharmaceuticals, Inc. (Nasdaq:CYCC), (Nasdaq:CYCCP) announced today progress with a pivotal trial plan for sapacitabine, its oral...
Cyclacel Pharmaceuticals to Present At BIO CEO & Investor Conference
February 02, 2009 07:00 ET
|
Cyclacel
BERKELEY HEIGHTS, N.J., Feb. 2, 2009 (GLOBE NEWSWIRE) -- Cyclacel Pharmaceuticals, Inc. (Nasdaq:CYCC) (Nasdaq:CYCCP) announced today that its President and Chief Executive Officer, Spiro Rombotis,...
Cyclacel Begins Phase 2 Study of Oral Sapacitabine in Patients With Previously Treated Non-Small Cell Lung Cancer
January 13, 2009 07:00 ET
|
Cyclacel
BERKELEY HEIGHTS, N.J., Jan. 13, 2009 (GLOBE NEWSWIRE) -- Cyclacel Pharmaceuticals, Inc. (Nasdaq:CYCC) (Nasdaq:CYCCP) announced today that the company has begun treating patients in a Phase 2, open...
Cyclacel Pharmaceuticals to Present At Two Upcoming Investor Conferences
November 13, 2008 13:34 ET
|
Cyclacel
BERKELEY HEIGHTS, N.J., Nov. 13, 2008 (GLOBE NEWSWIRE) -- Cyclacel Pharmaceuticals, Inc. (Nasdaq:CYCC) (Nasdaq:CYCCP) announced today that its President and Chief Executive Officer, Spiro Rombotis,...
Cyclacel Pharmaceuticals to Present At Rodman & Renshaw 10th Annual Healthcare Conference
November 07, 2008 10:49 ET
|
Cyclacel
BERKELEY HEIGHTS, N.J., Nov. 7, 2008 (GLOBE NEWSWIRE) -- Cyclacel Pharmaceuticals, Inc. (Nasdaq:CYCC), (Nasdaq:CYCCP) announced today that its President and Chief Executive Officer, Spiro Rombotis,...